AURO-RITONAVIR DIN 02523620
Health Canada record
| Active ingredient(s) | RITONAVIR 100 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J05AE03 RITONAVIR |
| Original market date | 08-Sep-2022 |
| Current status date | 08-Sep-2022 |
| Source | Health Canada DPD |
Establishment licence of the holder
Auro Pharma Inc — licence 101305, currently licensed, last inspection rating C (2023-09-27).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RITONAVIR
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02285533 | KALETRA | ABBVIE CORPORATION | Tablet | RITONAVIR 50 MG; LOPINAVIR 200 MG | Marketed |
| 02357593 | NORVIR | ABBVIE CORPORATION | Tablet | RITONAVIR 100 MG | Marketed |
| 02524031 | PAXLOVID | PFIZER CANADA ULC | Tablet | RITONAVIR 100 MG; NIRMATRELVIR 150 MG | Marketed |
| 02229137 | NORVIR | ABBVIE CORPORATION | Capsule | RITONAVIR 100 MG | Cancelled Post Market |
| 02229145 | NORVIR | ABBVIE CORPORATION | Solution | RITONAVIR 80 MG | Cancelled Post Market |
| 02241480 | NORVIR SEC | ABBVIE CORPORATION | Capsule | RITONAVIR 100 MG | Cancelled Post Market |
| 02527804 | PAXLOVID | PFIZER CANADA ULC | Tablet | RITONAVIR 100 MG; NIRMATRELVIR 150 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 27283 | 2021-12-23 | Abbreviated New Drug Submission (ANDS) |
International API supply for RITONAVIR
7 valid EDQM Certificates of Suitability from 7 holders. 17 active FDA Drug Master Files.
Request a quote for AURO-RITONAVIR